arGentis Pharmaceuticals, LLC

15 articles about arGentis Pharmaceuticals, LLC

• arGentis Pharmaceuticals, LLC Acquires Rights to Rheumatoid Arthritis Therapy Entering Phase I Clinical Trial; Partnering with University of Tennessee And Veterans Affairs Medical Center

  11/12/2009

• arGentis Pharmaceuticals, LLC Expands Scientific Advisory Board

  10/16/2009

• arGentis Pharmaceuticals, LLC Receives Orphan Drug Designation for European Union

  2/17/2009

• arGentis Pharmaceuticals, LLC Receives Favorable Opinion for European Orphan Drug Designation

  1/6/2009

• arGentis Pharmaceuticals, LLC Presents at Southeast BIO (SEBIO) 10th Annual Investor Forum

  12/10/2008

• arGentis Pharmaceuticals, LLC Files Patent on Nucleic Acid Sequences and Polymorphisms Predictive of Patient Responses to ARG201 an Immunotherapy for Late Phase Systemic Sclerosis

  7/1/2008

• arGentis Pharmaceuticals, LLC Release: Phase II Results for Low-Dose Oral Immune Tolerance Therapy (ARG201) in Systemic Scleroderma Published

  6/30/2008

• arGentis Pharmaceuticals, LLC Licenses Third Treatment for Dry Eye Syndrome

  5/12/2008

• Innova Memphis Inc. Invests In arGentis Pharmaceuticals, LLC

  4/21/2008

• arGentis Pharmaceuticals, LLC Receives Orphan Drug Designation

  2/8/2008

• arGentis Pharmaceuticals, LLC Signs Agreement with LifeCyte to Develop cGMP Facility

  9/24/2007

• arGentis Pharmaceuticals, LLC Signs Exclusive License Agreement with UTRF for Scleroderma Treatment

  8/14/2007

• Dr. William E. Cochran Joins arGentis, LLC Board of Directors

  7/11/2007

• arGentis Pharmaceuticals Appoints Scientific Advisory Board

  4/2/2007

• arGentis, LLC Licenses Second Therapy For Dry Eye Syndrome

  1/16/2007